Skip to main content

Table 3 Adverse events reported in all patients by CTP at time of event

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

CTP at time of AE

GC

MTX

IL-1 Inhibitor

IL-6 Inhibitor

Total

Grade 2

0

2 (allergic reaction [1], arthritis flare [1])

5 (MAS [1], hepatitis [1], rash [1], Strep pharyngitis [1], injection site reaction [1])

8 (fever [1}, rash [1], arthritis flare [2], headache [1], neutropenia [1], viral illness [1], infusion reaction [1])

15

Grade 3

0

0

2 (infections)b

0

2

Grade 4

0

0

0

1 (infusion reaction)

1

SAE

0

1a

2 (infections)b

1 (MAS)

3

  1. aAppendicitis and appendectomy
  2. b1 varicella (anakinra), 1 cellullitis (canakinumab)